Skip to main content

Dr. Jamie E. Chaft, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
20
In the NPI registry since
2008
Medicare patients seen, 2024
262

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Medical school: New York University School of Medicine
  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    NY license 247218
  • Internal Medicine Physician
    NY license 247218

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
262
Services billed
1,034
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes446222
Established patient office or other outpatient visit, 40-54 minutes389190
Established patient office or other outpatient visit, 20-29 minutes214105
New patient office or other outpatient visit, 60-74 minutes7373
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes4017
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes3012

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 26 payments worth $38,929 in total to this clinician.

By type
Consulting Fee$34,660
Travel and Lodging$3,297
Food and Beverage$973

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jan 6, 2025Eli Lilly and Company
Jan 6, 2025
Consulting Fee
Company’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES
$9,900
Nov 6, 2025AstraZeneca Pharmaceuticals LP
Nov 6, 2025
Consulting Fee
IMFINZI · Oncology
$4,920
Jun 9, 2025AstraZeneca Pharmaceuticals LP
Jun 9, 2025
Consulting Fee
IMFINZI · Oncology
$4,920
Nov 20, 2025AstraZeneca Pharmaceuticals LP
Nov 20, 2025
Consulting Fee
TAGRISSO · Oncology
$4,100
Dec 23, 2025EMD Serono, Inc.
Dec 23, 2025
Consulting Fee
Company’s descriptionAdvisory Board Participation (Fee For Service)
$3,800
May 12, 2025AstraZeneca UK Limited
May 12, 2025
Consulting Fee
IMFINZI · Oncology
Company’s descriptionResearch Related Service
$3,280
Dec 29, 2025Nuvation Bio Inc.
Dec 29, 2025
Consulting Fee
IBTROZI · Oncology
$2,100
Jul 9, 2025AstraZeneca UK Limited
Jul 9, 2025
Consulting Fee
TAGRISSO · Oncology
Company’s descriptionResearch Related Service
$1,640
Jan 14, 2025Merck Sharp & Dohme LLC
Jan 14, 2025
Travel and Lodging
VACCINE · travel to La Jolla, CA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$1,640
Jun 2, 2025AstraZeneca UK Limited
Jun 2, 2025
Travel and Lodging
travel to Chicago, IL · in-kind
Company’s descriptionResearch Related Service
$417
All 15 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 29, 2025Nuvation Bio Inc.
Dec 29, 2025
Consulting Fee
IBTROZI · Oncology
$2,100
Dec 23, 2025EMD Serono, Inc.
Dec 23, 2025
Consulting Fee
Company’s descriptionAdvisory Board Participation (Fee For Service)
$3,800
Nov 20, 2025AstraZeneca Pharmaceuticals LP
Nov 20, 2025
Consulting Fee
TAGRISSO · Oncology
$4,100
Nov 6, 2025AstraZeneca Pharmaceuticals LP
Nov 6, 2025
Consulting Fee
IMFINZI · Oncology
$4,920
Jul 9, 2025AstraZeneca UK Limited
Jul 9, 2025
Consulting Fee
TAGRISSO · Oncology
Company’s descriptionResearch Related Service
$1,640
Jun 9, 2025AstraZeneca Pharmaceuticals LP
Jun 9, 2025
Consulting Fee
IMFINZI · Oncology
$4,920
Jun 2, 2025AstraZeneca UK Limited
Jun 2, 2025
Travel and Lodging
travel to Chicago, IL · in-kind
Company’s descriptionResearch Related Service
$417
May 12, 2025AstraZeneca UK Limited
May 12, 2025
Consulting Fee
IMFINZI · Oncology
Company’s descriptionResearch Related Service
$3,280
Feb 6, 2025Merck Sharp & Dohme LLC
Feb 6, 2025
Travel and Lodging
VACCINE · travel to La Jolla, CA
Company’s descriptionProvided as part of a clinical research engagement.
$214
Jan 16, 2025Merck Sharp & Dohme LLC
Jan 16, 2025
Travel and Lodging
VACCINE · travel to La Jolla, CA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$154
Jan 15, 2025Merck Sharp & Dohme LLC
Jan 15, 2025
Travel and Lodging
VACCINE · travel to La Jolla, CA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$326
Jan 15, 2025Merck Sharp & Dohme LLC
Jan 15, 2025
Travel and Lodging
VACCINE · travel to La Jolla, CA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$221
Jan 14, 2025Merck Sharp & Dohme LLC
Jan 14, 2025
Travel and Lodging
VACCINE · travel to La Jolla, CA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$1,640
Jan 14, 2025Merck Sharp & Dohme LLC
Jan 14, 2025
Travel and Lodging
VACCINE · travel to La Jolla, CA · in-kind
Company’s descriptionProvided as part of a clinical research engagement.
$326
Jan 6, 2025Eli Lilly and Company
Jan 6, 2025
Consulting Fee
Company’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES
$9,900

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $6,453,551 in research payments for these studies, mostly to the institutions running them.

  • A randomized Phase 3 study of nivolumab after surgical resection and adjuvant chemotherapy in Non Small Cell Lung Cancer
    E.r. Squibb & Sons, L.l.c.
  • An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 …
    AstraZeneca Pharmaceuticals LP
  • A phase II study of induction AMG 510 mono- and combination therapy for surgically resectable stage IB-IIIB non-squamous NSCLC bearing a KRASG12C-mutation
    Amgen Inc.
  • NAUTIKA1 previously LCMC4
    Genentech, Inc.
  • A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
    Beigene, Ltd. · Completed · NCT05635708
  • A phase 3, multicenter, double-blind, placebo-controlled study assessing the efficacy and safety of olomorasib in combination with standard of care immunotherapy in participants with resected or unresectable kras G12C…
    Eli Lilly and Company
  • A Phase III, Randomised, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus SoC Chemotherapy Alone for the Treatment of Patients with Epidermal Growth F…
    AstraZeneca Pharmaceuticals LP
  • A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer
    AstraZeneca Pharmaceuticals LP
  • A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-sma…
    Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in New York

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 6, 2015), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1861659500. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.